Clinical Takeaway
Clinical trials show that cannabis-based products, particularly those containing THC, provide modest reductions in chronic pain compared to placebo, though the overall strength of evidence remains low to moderate. Benefits appear most consistent for neuropathic and mixed pain conditions, but are often accompanied by increased rates of adverse effects including dizziness, sedation, and cognitive changes. Patients and clinicians should weigh these modest analgesic benefits carefully against the risk profile when considering cannabinoids as part of a broader chronic pain management strategy.
#1 Cannabis-Based Products for Chronic Pain : An Updated Systematic Review.
Citation: Chou Roger et al.. Cannabis-Based Products for Chronic Pain : An Updated Systematic Review.. Annals of internal medicine. 2026. PMID: 41429020.
Design: 5 Journal: 3 N: 4 Recency: 3 Pop: 2 Human: 1 Risk: -2
This updated systematic review addresses the persistent clinical uncertainty regarding cannabinoid efficacy and safety in chronic pain management by synthesizing the latest randomized controlled trial evidence through July 2025. The stratification of cannabinoids by THC-to-CBD ratio provides clinically relevant categorization that can inform evidence-based prescribing decisions for patients when conventional analgesics are inadequate or poorly tolerated. Given the expanding regulatory approval and patient demand for cannabis-based products, this synthesis offers critical guidance for clinical decision-making and identifies evidence gaps requiring further investigation.
Quality Gate Alerts:
- Preclinical only
Abstract: BACKGROUND: Benefits and harms of cannabinoids for chronic pain are uncertain. PURPOSE: To update an evidence synthesis on cannabinoids for chronic pain. DATA SOURCES: Ovid MEDLINE, PsycINFO, Embase, the Cochrane Library, and Scopus to 28 July 2025. STUDY SELECTION: Randomized placebo-controlled trials. DATA EXTRACTION: Data extraction, risk of bias, and strength of evidence were dually reviewed. Cannabinoids were categorized by tetrahydrocannabinol (THC)-to-cannabidiol (CBD) ratio (high, comparable, or low), source (synthetic, purified, extracted), and administration method. DATA SYNTHESIS: 25 short-term (1 to 6 months) randomized controlled trials (n = 2303; 64% neuropathic pain) assessed cannabinoids. Oral synthetic/purified high THC-to-CBD (THC only) may slightly reduce and oromucosal, extracted, comparable THC-to-CBD ratio products probably slightly reduce pain severity (pooled differences, -0.78 and -0.54 points, respectively, [0 to 10 scale]), with moderate or large increased dizziness, sedation, and nausea. Among THC-only products, nabilone moderately reduced pain severity but dronabinol did not (pooled differences, -1.59 and -0.23 points, respectively). Low THC-to-CBD interventions may not improve outcomes. Although low THC-to-CBD mixed THC/CBD products may increase dizziness, sedation, and nausea, CBD alone may not increase harms. LIMITATION: Variability within categories; lack of product details; unclear U.S. availability of studied products; restricted to English-language studies. CONCLUSION: Comparable and high THC-to-CBD ratio cannabinoid products may result in small improvements in pain and increased common adverse events during short-term treatment of primarily neuropathic pain; among high-ratio THC-only products, nabilone (but not dronabinol) reduced pain. Low THC-to-CBD products may not improve outcomes. Studies are needed on long-term outcomes and other cannabis product types. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality, U.S
? This updated systematic review of randomized controlled trials underscores what many clinicians already recognize: the evidence for cannabinoids in chronic pain remains genuinely mixed and heterogeneous. The authors’ focus on THC-to-CBD ratios is clinically sensible since product composition varies dramatically across jurisdictions and preparations, yet most trials involve relatively small sample sizes and short follow-up periods that may not capture real-world efficacy or cumulative harms over months or years. Key confounders include publication bias favoring positive results, the challenge of adequate blinding in cannabis trials, variable pain phenotypes across studies, and the fact that many patients self-titrate and combine cannabinoids with other analgesics in practice. Clinicians should recognize that while some patients report meaningful pain relief, we lack robust evidence for specific cannabinoid ratios or dosing regimens that clearly outperform existing standard-of-care options, and individualized trials with careful monitoring for cognitive, psychiatric, and dependency-related adverse effects remain the most defens
Have thoughts on this? Share it:
